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INTRODUCTION: 
With the discovery of new drug molecules today low 
solubility is the main hurdle to be overcome. There are 
many techniques like solid dispersions, inclusion 
complexes with β-cyclodextrins, micronization, eutectic 
mixtures and spray-drying which can overcome this 
problem but among all liquisolid technique is most easy 
and cost effective technique. In liquisolid technique even 
though the drug is in a solid dosage form, it is held within 
the powder substrate in solution or, in a solubilised almost 
molecularly dispersed state, which contributes to the 
enhanced drug dissolution properties.
1
  
Definitions 
Liquid medication:  
Liquid medication includes liquid lipophilic drugs and 
drug suspensions or solutions of solid water insoluble 
drugs in suitable non-volatile solvent systems.
2
  
Liquisolid systems:  
Liquisolid system refers to powdered forms of liquid 
medications formulated by converting liquid lipophilic 
drugs, or drug suspensions or solutions of water insoluble 
solid drugs in suitable non-volatile solvent systems, into 
dry, non-adherent, free-flowing and readily compressible 
powder admixtures by blending with selected carrier and 
coating materials.
3   
 
Non-volatile solvent:  
Non-volatile solvent may be hydrophilic or lipophillic in 
nature depending upon the type of formulation like 
immediate release or sustained release. Non solvent should 
be inert, high boiling point, water miscible.
4 
 
Carrier material:  
Carrier material refers to a preferably porous material 
possessing sufficient absorption properties, such as 
microcrystalline and amorphous cellulose, which 
contributes in liquid absorption.
4 
Coating material:  
Coating material refers to a material possessing fine and 
highly adsorptive particles, such as various types of silica, 
which contributes in covering the wet carrier particles and 
displaying a dry looking powder by adsorbing any excess 
liquid. Furthermore replacement of commonly used carrier 
and coating materials like Avicel and Aerosil respectively 
with Fujicalin and Neusilin led to considerably higher 
liquid adsorption capacity because of large specific surface 
area and good flow property.
4,5
 
Disintegrant:  
5 % of disintegrant is used in formulation, mainly Sodium 
Starch glycolate is used as disintegrant. 
Basics of Liquisolid System 
Spireas et al developed a mathematical approach for 
formulation of liquisolid compact.
6
 This approach is 
mainly to calculate required amount of carrier and coating 
material in liquisolid technique. As a powder can retain 
only limited amount of liquid while maintaining acceptable 
flow and compression properties, this approach is based on 
the flowable (Ф-value) and compressible (Ψ-number) 
liquid retention potential.
6 
 
Flowable liquid retention potential (ϕ-value) is defined 
as the maximum weight of liquid that can be retained per 
unit weight of powder material in order to produce an 
acceptably flowing liquid/powder admixture. 
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Compressible liquid retention potential (ѱ-value) is 
defined as the maximum weight of liquid that can be 
retained per unit weight of the powder material in order to 
produce an acceptably compressible liquid or powder 
admixture.
7
  
The excipient ratio (R) or the carrier: coating material ratio 
is represented as follows: 
R = Q / q  …….  (equation. 1) 
Depending on the excipient ratio (R) of the powder 
substrate an acceptably flowing and compressible 
liquisolid system can be obtained only if a maximum 
liquid load on the carrier material is not exceeded. This 
liquid/carrier ratio is termed “liquid load factor (Lf) [w/w] 
and is defined as the weight ratio of the liquid formulation 
(W) and the carrier material (Q) in the system: 
Lf=W/Q  ……..  (equation. 2) 
The liquid load factor that ensures acceptable flow ability 
(
Φ
Lf ) can be determined by: 
ϕ
Lf = ϕ+ ϕ . (1/R)…….. (equation. 3) 
Where ϕ  and ϕ  are the Ф-values of the carrier and coating 
material respectively. Similarly, the liquid load factor for 
production of liquisolid systems with acceptable 
compactability (
ѱ
Lf) can be determined by: 
ѱ
Lf = ѱ+ ѱ. (1/R)…… (equation. 4) 
Where Ψ and ѱ are the Ψ-numbers of the carrier and 
coating material respectively. Therefore, the optimum 
liquid load factor (L0) required to obtain acceptably 
flowing and compressible liquisolid systems is equal to 
either 
ϕ
Lf or 
ѱ
Lf, whichever represents the lower value.
7
 
Classification of liquisolid systems 
Based on the type of liquid medication contained therein, 
liquisolid systems may be classified into three sub-groups. 
1) Powdered drug solutions 
2) Powdered drug suspensions 
3) Powdered liquid drugs 
Powdered drug solutions and suspensions may be 
produced from the conversion of drug solutions or drug 
suspensions into liquisolid systems and powdered liquid 
drugs are produced from the formulation of liquid drugs 
into liquisolid systems. 
Simultaneously, based on the formulation technique used, 
liquisolid systems may be classified into two categories 
namely, 
1) Liquisolid compacts 
2) Liquisolid microsystems 
The term “liquisolid compacts” refers to immediate or 
sustained release tablets or capsules prepared and 
combined with the inclusion of appropriate adjuvants 
required for tabletting or encapsulation, such as lubricants, 
and for rapid or sustained release action, such as 
disintegrants or binders. 
The term “liquisolid Microsystems” refers to capsules 
prepared by combining the drug with 
carrier and coating materials with inclusion of an additive 
e.g., PVP in the liquid medication wherein the resulting 
unit size may be as much as five times that of liquisolid 
compacts.
5
 
Main components of liquisolid technique are represented 
in table no 1. 
Table 1: Components of Liquisolid Technique 
 
Pre-formulation Studies 
1) Solubility studies: Solubility studies are carried out to 
select the best non volatile solvent for dissolving or 
suspending the drug in non - volatile solvent. Solubility 
studies are carried by preparing saturated solutions of 
drug in non-volatile solvent. Saturated solutions are 
prepared by adding excess of drug to vehicles and 
shaking them on shaker for 24 hour under constant 
vibration. Then the solutions are filtered diluted 
suitably and analyzed spectrophotometrically at a 
particular wavelength.
7 
The review of the solubility of 
different drugs in various non volatile solvent is shown 
in table no 2. 
 
 
Drug Candidates Hydrochlorothiazide, Digitoxin, Prednisolone Hydrocortisone, Spironolactone, 
Digoxin etc. 
Non Volatile Liquids Poly Ethylene Glycol 200, Poly Ethylene Glycol 300, Poly Ethylene Glycol  400, 
Glycerine, Propylene Glycol,  fixed oils.  
Carrier Materials Microcrystalline Cellulose PH 101, Microcrystalline Cellulose PH 200, Lactose, 
Methyl Cellulose, Ethyl Cellulose, Starch1500, Ethocel, Eudragit RL, Eudragit 
RS 12, Hydroxy Propyl Methyl Cellulose K4M, Hydroxy Propyl Methyl 
Cellulose K100M, Xanthum Gum, Guargum. 
Coating Materials Aerosil 200, Silica (Cab-O-Sil M5), Syloid 244FP, and Colloidal Silicon 
Dioxide. 
Disintegrants Sodium Starch Glycolate (Explotab, Primogel), Croscarmellose Sodium, Cross 
Polyvinyl Pyrrolidine, Pregelatized Starch. 
Glidant Talc 
Lubricant  Magnesium Stearate  
Release retardant material Eudragit RS, RL, Hydroxy Propyl Methyl Cellulose K100M, K15M, K4M. 
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Table 2: Review of the Solubility of Drugs in Various Non Volatile Solvent 
 
Drug Non-volatile solvent Solubility(mg/ml) 
Carbamazepine
8
 Propylene Glycol  
Poly Ethylene Glycol 200  
Poly Ethylene Glycol 400  
Glycerin  
Polysorbate 80 
40.896 
87.668 
71.820 
7.789 
45.831
 
Famotidine
9
 Propylene Glycol   
Polyethylene Glycol-600  
 
9.5693 
6.149 
Etoricoxib
10 
Propylene Glycol  
Poly Ethylene Glycol 200  
Poly Ethylene Glycol 400  
Tween 20  
Tween 80  
44.95 
62.16 
65.08 
34.42 
36.80 
Nimesulide
11 
Propylene Glycol  
Poly Ethylene Glycol 400 
2.760 
63.5 
Glibenclamide
12 
Propylene Glycol  
Poly Ethylene Glycol 300 
Polyethylene Glycol 400 
3 
12 
15 
Propranolol Hydrochloride
13 
Propylene Glycol  
Poly Ethylene Glycol 200 
Poly Ethylene Glycol 400  
Glycerin  
Polysorbate  
10.29 
7.98 
7.97 
3.91 
1.33
 
 
2) Determination of angle of slide: To determine angle 
of slide required amount of carrier is weighed and 
placed at one end of a metal plate with a polished 
surface. The end is gradually raised till the plate 
becomes angular to the horizontal at which powder is 
about to slide. This angle is known as angle of slide. It 
was used as a measure of the flow properties of 
powders. Angle of 33° is regarded as optimum.
5
 
3)  Determination of flowable liquid retention 
potential: The flowable liquid-retention potential (Φ 
value) of a powder material describes its ability to 
retain a specific amount of liquid while maintaining 
good flow properties. The Φ value is defined as the 
maximum weight of liquid, (Wliquid) that can be retained 
per unit weight of the sorbent (Wsolid), yielding a 
mixture with acceptable flowability, 
                                                     Wliquid/WSolid                                                     
As the flowable liquid-retention potential of the carrier 
material is approached, the liquid is held entirely in the 
interior of the particles. This maintains the surface of 
carrier material relatively dry, thus yielding powders with 
acceptable flow properties. When the Φ value is exceeded, 
the interior of particles become saturated, resulting in the 
formation of a liquid layer on the available surface of 
carrier particles.
5
  
Calculation of liquid load factor (Lf):  It is defined as the 
ratio of weight of liquid medication (W) to weight of 
carrier material (Q). Different concentrations of non 
volatile solvents are taken and the drug is dissolved and 
the carrier coating material is added and blended. 
Lf=W/Q 
      W=ratio of weight of liquid medication 
      Q= weight of carrier material 
      The liquid load factor that ensures acceptable 
flowability (Lf), and can be measured by: 
Lf= (1/R) 
14
 
 
4)  Liquisolid compressibility test: It was developed to 
determine Ψ values and involves steps such as 
preparing carrier coating material admixture systems, 
preparing several uniform liquid/powder admixtures to 
tablets, determining average hardness, measuring of 
average liquid content of crushed tablets, as well as 
determining plasticity, sponge index and Ψ value and 
Lf.
14
 
Preparation of Liquisolid Tablets 
A calculated quantity of drug should be dispersed in the 
non volatile solvent system (Polysorbate 80, Poly Ethylene 
Glycol-200) termed as liquid vehicle with different drug: 
vehicle ratio. Then resulting hot medication should be 
incorporated into carrier and coating material under 
continuous mixing in a mortar. Mixing process is to be 
carried out in three steps which is shown in fig. no. 1. 
Step1. System is blended at an appropriate mixing rate of 
one rotation per second for approximately one minute in 
order to evenly distribute liquid medication in the powder. 
Step 2: The liquid / powder admixture is evenly spread as a 
uniform layer on the surface of a mortar and left standing 
for approximately 5 minute to allow dug solution to be 
absorbed in the interior of powder particle. 
Step 3: Powder is scraped off the motor surface by mean of 
aluminium spatula and then blended with disintegrant like 
Sodium Starch Glycolate and other remaining additives are 
added according to their application and mixed for a period 
of 10 to 20 minute in a mortar. 
The final mixture should be compressed using the manual 
tabletting machine to achieve tablet hardness.
15
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Figure 1: Steps of Liquisolid Technique
 
Characterisation: 
1) Differential scanning calorimetry (DSC): Is 
a thermoanalytical technique in which the difference in the 
amount of heat required to increase the temperature of a 
sample and reference is measured as a function of 
temperature.  Both the sample and reference are 
maintained at nearly the same temperature throughout the 
experiment. It is used to know the possible interactions 
between drug and excipients used in the formulation. If the 
characteristic peak for the drug is absent in the DSC 
thermogram, there is an indication that the drug is in the 
form of solution in liquisolid formulation and hence it is 
molecularly dispersed within the system. Thermal 
properties of the untreated drug and prepared samples are 
analyzed by DSC. About 5 mg of sample is heated in a 
hermetically sealed aluminium pans. Heat runs for each 
sample were set from 30°C to 350°C at a heating rate of 
10°C/ min, using nitrogen atmosphere of flow rate 100ml/ 
minute.
16
 
2) Fourier transform infra-red spectroscopy (FTIR): It 
is a technique which is used to obtain 
an infrared spectrum of absorption, emission and Raman 
scattering of a solid, liquid or gas. FTIR spectrometer 
simultaneously collects spectral data in a wide spectral 
range. FTIR spectrum of the drug and the prepared 
samples were subjected to IR spectrophotometer under 
identical conditions by Potassium Bromide pellet 
technique. Spectrum is collected over a region of 4000-400 
cm
-1
.
16 
3) X ray diffraction (XRD): A primary use of the 
technique is the identification and characterization of 
compounds based on their diffraction pattern. For the 
characterization of crystalline state, (XRD) patterns are 
determined for physical mixture of drug and excipients 
used in formulation and for the prepared liquisolid 
compacts. Absence of constructive specific peaks of the 
drug in the liquisolid compacts in X-ray diffractogram 
specify that drug has almost entirely converted from 
crystalline to amorphous or solubilised form. Such lack of 
crystallinity in the liquisolid system was understood to be 
as a result of drug solubilization in the liquid vehicle i.e., 
the drug has formed a solid solution within the carrier 
matrix. This solubilization of drug in the liquisolid 
compacts it may contribute to the consequent improvement 
in the apparent solubility and enhancement of dissolution 
rate of the drug.
14
 
Precompression Studies of Liquisolid Preparation 
1) Angle of repose: Angle of repose can be measured by 
fixed funnel method. The frictional forces in loose powder 
or granules can be measurement by the angle of repose. 
This is the maximum angle possible between the surface of 
a pile of powder or granules and the horizontal plane. 
Thus, r being the radius of the base of the conical pile.
17
 
This is shown in table no 3.
 
Tan θ = h/r 
Table 3: Angle of Repose
17 
 
2) Bulk density: Bulk density refers to the measure used 
to describe a packing of particles or granules. Bulk density 
is defined as the mass of powder divided by the bulk 
volume and is expressed in grams per milliliter (g/mL) 
although the international unit is kilogram per cubic meter 
(1 g/mL = 1000 kg/m
3
) because the measurements are 
Drug+ non volatile 
solvent  
Hot medication is 
added into  carrier 
and coating material 
This mixture is  
continously mixed 
in a motar 
Mixing process is 
carried out in three 
steps 
Step 1: Mixture is rotated 
for 1 rotation per second 
for one minute for 
complete mixing of liquid 
medication in powder 
Step 2: This mixture is 
spread over the motar for 
5 minute so that drug get 
absorbe in the intrior  of 
powder  
Step 3: Powder is 
scraped off  
Disintegrant is 
added and left for 
10-20 minutes 
Other additive are 
added and the  
punched into 
tablets. 
Flow property Angle of repose (degrees) 
Excellent 25 – 30 
Good 31 – 35 
Fair-aid not needed 36 – 40 
Passable – may hang up 41 – 45 
Poor – must agitate, vibrate 46 – 55 
Very poor 56 – 65 
Very, very poor >66 
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made using cylinders. It may also be expressed in grams 
per cubic centimetre (g/cm
3
).  The equation for 
determining bulk density (ρb) is 
17 
ρb = M / Vb 
where  ρb  = Bulk density 
M = Mass of sample in g 
Vb = Total volume of packing 
3) Tapped density: Tapped density can be defined as 
mass of blend in the measuring cylinder divided by its 
tapped volume.
17 
ρt = M / Vt 
Where  ρt = Tapped density 
M = Mass of blend in g 
Vt = Tapped volume of blend in cm
3
 
4) Carr’s index: The compressibility index (Carr’s Index) 
is a measure of the propensity of a powder to be 
compressed. It is determined from the bulk and tapped 
densities and is calculated using the following formulas 
and is shown in table no. 4:
 
Carr’s Index = ρt - ρb/ρt *100 
ρb = bulk density 
   ρt = tapped density.
17 
Table 4: Carr’s Index17 
 
 5) Hausner’s ratio: A flow property of powder mixure 
can be determined by Hausner’s ratio. It is calculated by 
following formula and is shown in table no. 5 
Hausner’s ratio = Tapped density/ Bulk density 
A Hausner ratio greater than 1.25 is considered of poor 
flow ability
18 
Table 5: Hausner Ratio
18 
 
 
 
Post Compression Evaluations 
1) Hardness: Monsanto hardness tester can be used for 
the determination of the hardness. The tablet to be 
tested was held between a fixed and moving jaw and 
reading of the indicator adjusted to zero. The force 
applied to the edge of the tablet is gradually increased 
by moving the screw knob forward until the tablet 
breaks. Reading is noted down and is expressed in 
kg/cm.
19 
2) Thickness: The crown to crown thickness of tablets is 
measured by Vernier Caliper. It is expressed in mm. the 
thickness variation allowed are ± 5% of the size of the 
tablet.
19 
3) Weight variation: 20 tablets are selected randomly 
from the lot and weighed individually to check for 
weight variation.
19
 Pharmacopoeial limits are shown in 
table no 6. 
Table 6 Pharmacopoeial Limits of Weight Variation
19 
 
4) Uniformity of Drug content:  
5) The drug content can be determined by triturating 
sufficient amount of tablets and powder equivalent to 
average weight was added in 100 ml of suitable buffer 
solution. Followed by stirring for 30 min. Dilute 
suitably and the absorbance of resultant solution was 
measured spectrophotometrically.
19 
6) In-vitro drug release studies: The release rate of drug 
from tablets can be determined using USP dissolution 
testing apparatus 2 (paddle method). The dissolution 
test performed using 900 ml of suitable buffer solution 
at 37±0.5ºC.
19
 
7) Friability: The friability of the tablet can determined 
using Roche Friabilator. It is expressed percentage (%). 
10 tablets were initially weighed (W
initial
) and 
transferred into the friabilator. The friabilator was 
operated at 25 rpm for 4 minutes. The tablets were 
weighed again (W
final
). And the % friability was 
calculated as. 
F= (Winitial)-(Wfinal)/(Winitial) × 100
19 
Advantages
20 
1) Improved bioavailability of orally administered water 
insoluble or poorly soluble drugs. 
2) Industrially applicable. 
3) Useful for the formulation of oily drugs/liquid drugs. 
4) Drug release can be modified using different carriers 
and additives like PVP, PEG 60000, Hydroxy Propyl 
Methyl Cellulose and Eudragit etc. 
5) A number of poorly soluble drugs can be formulated 
in to the system. 
6) Production cost is low compared to that of preparation 
of soft gelatin capsules. 
Flow property C.I (%) 
Excellent  ≤10 
Good  11 – 15 
Fair  16 – 20 
Passable 21 – 25 
Poor 26 – 31 
Very  poor 32 – 37 
Very, very poor >38 
Flow property Hausner ratio 
Excellent  1.00 – 1.11 
Good  1.12 – 1.18 
Fair  1.19 – 1.25 
Passable 1.26 – 1.34 
Poor 1.35 – 1.45 
Very  poor 1.46 – 1.59 
Very, very poor >1.60 
Limit  IP/BP USP 
10% 80 mg or less 130mg or less 
7.5% More than 80mg or 
Less than 250mg 
130mg to 324mg 
5% 250mg or more More than 324mg 
Chandel et al                                         Journal of Drug Delivery & Therapeutics; 2013, 3(4), 131-137    136 
 © 2011, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
7) Method of preparation is very simple and it is similar 
to that of conventional tablets preparation. 
8) Drug can be dispersed molecularly in the formulation. 
9) Enhance the bioavailability when compared to that of 
conventional tablets. 
10) It does not involve the operations like micronization, 
nanonization of particles. 
11) This system is specifically for the powdered liquid 
medications. 
Disadvantages/Limitations
20 
1) High solubility of drug in the non-volatile liquid drugs 
for the improvement of dissolution rate and 
bioavailability. 
2) It requires excipients of high adsorption properties and 
high specific surface area. 
3) It is not applicable to high dose insoluble drugs (>100 
mg). 
4) During compression sometimes liquid drug may be 
squeezed out of the tablet result in improper hardness. 
Applications
20 
1) Enhancement of solubility and dissolution rate in drugs 
like Indomethacin, Famotidine, Furosemide, Naproxen, 
Prednisolone, Bromhexine Hydrochloride, 
Carbamazapine, Rofecoxib, Piroxicam etc. 
2) Enhancement of bioavailability of drugs like 
Atorvastatin Calcium, Hydrochlorthiazide, 
Repaglinide, Famotidine etc. 
3) Formulation of sustained release tablets by the use of 
hydrophobic carriers like Propanolol Hydrochloride, 
Tramadol Hydrochloride, and Theophylline etc. 
4) It is also applicable in probiotics. 
5) Controlled release formulations are also prepared by 
the use of different carriers that may show the zero 
order release similar to osmotic pumps. 
6) This technique is widely employed for liquid lipophilic 
drugs / oily drugs. 
Liquisolid Technique in the Formulation of Sustained 
Release Tablets 
Development of sustained release oral dosage form is 
beneficial for optimal therapy in terms of efficacy, safety 
and patient compliance. Several methods have been 
developed to this end or to achieve this aim. It is suggested 
that liquisolid technique has the potential to be optimised 
for the reduction of drug dissolution rate and there by 
production of sustained release system.
21
 Sustained release 
dosage forms are designed to release the drug at a 
predetermined rate by maintaining a constant drug release 
for specific period of time with minimum side effects in 
terms of efficacy, safety and patient compliance. Ideally, 
controlled release formulations will provide therapeutic 
concentration of the drug in the blood which is maintained 
throughout the dosing interval. Liquisolid technique is a 
new approach to alter the dissolution properties of the drug 
by using hydrophobic carriers instead of hydrophilic 
carriers.
3
 The presence of non-volatile solvent reduces the 
glass transition temperature (Tg) of polymer and imparts 
flexibility. Therefore, reduction of Tg of the polymer 
might be the reason for the release prolongation of 
liquisolid tablets. In the temperature above the Tg, a better 
coalescence of the polymer particle occurs that form a fine 
network and a matrix with lower porosity an higher 
tortusity. In this way, the drug is surrounded by the 
polymer network, resulting in the restricted leaching of the 
drug thus sustained the release of drug from the liquisolid 
matrix.
21
 Review of the drug molecules with sustained 
release liquisolid compact is shown in table no 7. 
 
Table 7 Review of the Drug Molecules with Sustained Release Liquisolid Compact 
 
 
 
 
 
CONCLUSION:  
Nowadays, new chemical entities often possess a high 
molecular weight and a high lipophilicity, especially 
poorly soluble drugs. Poor bioavailability is solely caused 
by low water solubility. One of the techniques to increase 
solubility is liquisolid technique which is discussed above. 
As highest drug release rates are observed with liquisolid 
technique, liquisolid compacts may be optimized by 
selection of proper non volatile solvent, carrier and coating 
materials.  
 
 
 
 
 
 
 
 
 
Drug Polymer Used In Sustained Release Formulation 
Tramadol Hydrochloride
22 
Hydroxy Propyl Methyl Cellulose K4M  
Propranolol Hydrochloride
23 
Hydroxy Propyl Methyl Cellulose (4000 mPa·s) 
Metoprolo Succinate
24 
Hydroxy Propyl Methyl Cellulose K15M 
Theophylline
25 
Hydroxy Propyl Methyl Cellulose (4000 mPa·s) 
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